**May, 2007**

[CURRICULUM VITAE]{.underline}

[Name]{.underline}: Matthew R. Young, Ph.D.

[Citizenship]{.underline}: United States

[Education]{.underline}:

1985 B.A., Chemistry, Brooklyn College, City University of New York, New
York, NY

1990 Ph.D., Biochemistry, University of Maryland at Baltimore, Dept. of
Biological Chemistry, School of Medicine, Baltimore, MD

[Brief Chronology of Employment]{.underline}:

1985-1990 Predoctoral Fellow, Department of Biological Chemistry, School
of Medicine, University of Maryland at Baltimore, Baltimore, MD

1990-1995 Postdoctoral Fellow, Laboratory of Molecular Virology and
Carcinogenesis, Advanced BioScience Laboratories, Inc., Basic Research
Program, National Cancer Institute, Frederick Cancer Research &
Development Center, Frederick, MD

1995-1996 IRTA Fellow, Inorganic Carcinogenesis Section, Laboratory of
Comparative Carcinogenesis, National Cancer Institute, Frederick Cancer
Research & Development Center, Frederick, MD

1996-1999 IRTA Fellow, Gene Regulation Section, Laboratory of
Biochemical Physiology, National Cancer Institute, Frederick Cancer
Research & Development Center, Frederick, MD

2000-2003 Staff Scientist, Gene Regulation Section, Basic Research
Laboratory, Center for Cancer Research, NCI at Frederick, Frederick, MD

2003-Date Staff Scientist, Gene Regulation Section, Laboratory of Cancer
Prevention, Center for Cancer Research, NCI at Frederick, Frederick, MD

[Honors and Other Special Scientific Recognition]{.underline}:

1987-1988 National Institutes of Health Predoctoral Fellowship,
University of Maryland, Baltimore, MD

1994 National Research Council Research Associateship, United States
Army Medical Research Institute of Infectious Disease, Frederick, MD

1997-1988 National Institutes of Health Fellows Award for Research
Excellence

1999 AACR-Bristol-Myers Squibb Young Investigator Award, American
Association for Cancer Research, Inc.

1999 NIH Fellows Award for Research Excellence (FARE) Award

2001 On-the Spot Award: High impact contribution to GRS Site Visit
Proposal and Presentation

[Invited Presentations]{.underline}:

Proteolytic cleavage of the EIAV nucleocapsid protein during endogenous
reverse transcription. Retrovirus Meeting, Cold Spring Harbor
Laboratory, 1993

Dominant negative Jun expression protects transgenic mice against skin
tumor promotion, Experimental Therapeutics of Human Cancer, 1998

Dominant negative Jun expression protects transgenic mice against skin
tumor promotion, AACR 90^th^ Annual Meeting, 1999

Fra-1 regulated genes as targets for cancer prevention, Cancer Research
UK Centre for Cell & Molecular Biology at The Institute of Cancer
Research, 2003

Transcription Factors as Target, IBS Meeting, 2003

Molecular Targets for Nutritional Intervention, Division of Cancer
Prevention Conference, 2005

[Publications]{.underline}:

1.  Young, M.R., Hu, L.T., Zachary, A. and Wolfe, P.B.: Expression of
    acid phosphatase-β- galactosidase hybrid proteins prevents
    translocation of a subset of yeast secreted proteins. *J. Biol
    Chem.* 265: 19824-19832, 1990.

2.  Menéndez-Arias, L., Young, M. and Oroszlan, S.: Purification and
    characterization of the mouse mammary tumor virus protease expressed
    in Escherichia coli. *J. Biol. Chem.* 267: 24134-24139, 1992.

3.  Rice, W.G., Schaefer, C.A., Graham, L., Bu, M., McDougal, J.S.,
    Orloff, S.L.,Villinger, F., Young, M., Oroszlan, S., Fesen, M.R.,
    Pommier, Y., Mendeleyev J. and Kun, E.: The site of antiviral action
    of 3-nitrosobenzamide on the infectivity process of human
    immunodeficiency virus in human lymphocytes. *Proc. Natl. Acad. Sci.
    USA* 90: 9721-9724, 1993.

4.  Nagy, K., Young, M., Baboonian, C., Merson, J., Whittle, P. and
    Oroszlan, S.: Prevention of primary HIV-1 infection in vitro by
    proteinase inhibitors. *J. Virol.* 68: 757-765, 1994.

5.  Zhao, Q., Young, M.R., Diwan, B.A., Coogan, T.P. and Waalkes, M.P.:
    Association of arsenic-induced malignant transformation with DNA
    hypomethylation and aberrant gene expression. *Proc. Natl. Acad.
    Sci. USA* 94 (20): 10907-10912, 1997.

6.  Huang, C., Ma, W.-Y., Young, M.R., Colburn, N.H. and Dong, Z.:
    Shortage of mitogen-activated protein (MAP) kinase is responsible
    for resistance to AP-1 transactivation and transformation in mouse
    JB6 P- cells. *Proc. Natl. Acad. Sci. USA* 95: 156-161, 1998.

7.  Watts, R.G., Huang, C., Young, M.R., Li, J.J., Dong, Z., Pennie,
    W.D. and Colburn, N.H.: Expression of Dominant Negative Erk2
    Inhibits AP-1 Transactivation and Neoplastic Transformation.
    *Oncogene* 17: 3493-3498, 1998.

8.  Young, M.R., Li, J.-J., Rincon, M., Flavell, R.A., Sathyanarayana,
    B.K., Hunziker, R. and Colburn, N.H.: Transgenic mice demonstrate
    AP-1 transactivation is required for tumor promotion. *Proc. Natl.
    Acad. Sci. USA* 96: 9827-9832, 1999.

9.  Pennie, W.D., Hegamyer, G.A., Young, M.R. and Colburn, N.H.:
    Specific methylation events contribute to the transcriptional
    repression of the mouse tissue inhibitor of metalloproteinases-3
    gene (TIMP-3) in neoplastic cells. *Cell Growth & Diff*. 10:
    279-286, 1999.

10. Davis, M.A., Flaws, J.A., Young, M. and Colburn, N.H.: Effect of
    ceramide analog C2 on intracellular glutathione determines apoptotic
    or necrotic cell death of JB6 tumor cells. *Tox. Sci.* 53: 48‑55,
    2000.

11. Hsu, T-C., Young, M.R., Cmarik, J. and Colburn, N.H.: Activator
    protein-1 (AP-1)- and nuclear factor-κB (NF-κB)-dependent
    transcriptional events in carcinogenesis. *FORUM Free Radical
    Biology & Medicine* 28: 1338-1348, 2000.

12. Li, J-J., Cao, Y., Young, M.R. and Colburn, N.H.: Induced expression
    of dominant negative cJun down regulates NFκB and AP-1 target genes
    and suppresses tumor phenotype in human keratinocytes. *Molec.
    Carcinogenesis* 29: 159-169, 2000.

13. Hsu, T-C., Nair, R., Tulsian, P., Hegamyer, G., Young, M.R. and
    Colburn, N.H.: Transformation non-responsive cells owe their
    resistance to lack of P65/NF-κB activation. *Cancer Res.* 61:
    4160-4168, 2001.

14. Young, M.R., Nair, R., Bucheimer, N., Tulsian, P., Hsu, T-C. and
    Colburn, N.H.: Transactivation of Fra-1 and Consequent Activation of
    AP-1 occur Erk Dependently. *Mole. Cell. Biol*. 22: 587-598, 2002.

15. Thompson E.J., MacGowan J., Young, M.R., Colburn, N. and Bowden,
    G.T.: A dominant negative c-jun specifically blocks okadaic
    acid-induced skin tumor promotion. *Cancer Res.* 1: 62 (11):
    3044-3047, 2002.

16. Young, M.R., Farrell, L., Lambert, P., Awasthi, P. and Colburn,
    N.H.: Protection against human papillomavirus type 16-E7
    oncogene-induced tumorigenesis by *in vivo* expression of
    dominant-negative c-jun. *Molecular Carcin.* 34: 72-77, 2002.

17. Dhar, A., Young, M.R. and Colburn, N.H.: The role of AP-1, NF-κB and
    ROS/NOS in skin carcinogenesis: The JB6 model is predictive. *Mole.
    Cell Biochem*. 234: 185-193, 2002.

18. Thompson, E.J., MacGowan, J., Young, M.R., Colburn, N.H. and Bowden,
    G.T.: A dominant negative c-jun specifically blocks okadaic acid
    induced skin tumor promotion. *Cancer Res.* 62: 3044-3047, 2002.

19. Young, M.R., Yang, H.S. and Colburn, N.H.: Promising molecular
    targets for cancer prevention: AP-1, NF6B, and Pdcd4. *Trends in
    Molecular Medicine* 9: 36-41, 2003.

20. Cooper, S., Young, M.R., Colburn, N.H. and Bowden, G.T.: Expression
    of Dominant Negative c-jun Inhibits UVB Induced Squamous Cell
    Carcinoma Number and Size in an SKH-1 Hairless Mouse Model. *Mole.
    Cancer Res.* 1: 848-854, 2003.

21. Hou, D-X., Kai, K., Li, J-J., Lin, S., Terahara, N., Wakamatsu, M.,
    Fujii, M., Young, M.R. and Colburn, N.H.: Anthocyanidins inhibit
    activator protein l activity and cell transformation:
    structure-activity relationship and molecular mechanisms.
    *Carcinogenesis* 25: 29-36, 2004.

22. Hu, J., Haseebuddin, M., Young, M.R., and Colburn, N.H.: Suppression
    of p65 phosphorylation coincides with inhibition of IkappaBalpha
    polyubiquitination and degradation. Mole. Carcino. 44: 274-284,
    2005.

23. Schmid, T. and Young, M.R.: Lights on for low oxygen: A noninvasive
    mouse model useful for sensing oxygen deficiency. Mole.
    Interventions 6: 20-22, 2006.

24. Young, M.R. and Colburn, N.H.: Fra-1 a Target for Cancer Prevention
    or Intervention. *Gene* 379: 1-11, 2006.

25. Shen, Q., Zhang, Y., Uray, I., Hill, J., Kim H., Lu, C., Young,
    M.R., Gunther, E., Hilsenbeck, S., Chodosh, L., Colburn, N.H. and
    Brown, P.: The AP-1 transcription factor regulates postnatal mammary
    gland development. *Dev. Biol*. 295: 589-603, 2006.

26. Ruocco, K.M., Goncharova, E.I., Young, M.R., Colburn, N.H., McMahon,
    J.B., and Henrich, C.J.: A High-Throughput Cell-Based Assay to
    Identify Specific Inhibitors of Transcription Factor AP-1. J Biomol
    Screen 12: 133-139, 2007.

27. Matthews, C.P., Birkholz, A.M., Baker, A.R., Perella, C.M., Beck,
    G.R. Jr., Young, M.R., Colburn, N.H. Dominant-negative activator
    protein (TAM67) targets cyclooxygenase-2 and osteopontin under
    conditions in which it specifically inhibits tumorigenesis. Cancer
    Res. 67: 2430-2438, 2007.